MetaboLightsapplication/xmlftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS14111/m_MTBLS14111_LC-MS_positive_reverse-phase_metabolite_profiling_v2_maf.tsvftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS14111/m_MTBLS14111_LC-MS_negative_reverse-phase_metabolite_profiling_v2_maf.tsvftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS14111/s_MTBLS14111.txtftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS14111/i_Investigation.txtftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS14111/a_MTBLS14111_LC-MS_negative_reverse-phase_metabolite_profiling.txtftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS14111/a_MTBLS14111_LC-MS_positive_reverse-phase_metabolite_profiling.txtprimaryOK200ftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS14111<p>Metabolite identification was performed by matching accurate mass-to-charge ratio (m/z), retention time, and MS/MS fragmentation spectra against public databases (HMDB, Metlin, MassBank, and GNPS) and a CSF-specific metabolite library, with a mass tolerance of ≤5 ppm and MS/MS similarity score ≥0.7. Isotopes and adducts were annotated using CAMERA or similar tools, and metabolites were classified based on their chemical class and biological function for downstream statistical analysis.</p>MetaboLightsPublicLiquid Chromatography MS - negative - reverse-phaseLiquid Chromatography MS - positive - reverse-phase<p>Chromatographic separation was performed on an Agilent 1290 Infinity II UHPLC system equipped with an Agilent 1290 Infinity II autosampler, using two complementary columns: an ACQUITY UPLC BEH C18 reverse-phase column (both 2.1 × 150 mm, 1.7 μm), each protected by a matching guard column. The column temperature was maintained at 45 °C, with mobile phases composed of acetonitrile, water, ammonium acetate, and formic acid, optimized for broad-spectrum metabolite detection in cerebrospinal fluid.</p>Characterization Epstein-Barr Virus-Associated Encephalitis via Identification of Metabolomic Biomarkers.Southern medical UniversityMuzi WenCerebrospinal fluidPooled samplemass spectrometry assay<p>Frozen CSF samples were thawed on ice and centrifuged at 10,000 g for 10 min at 4 °C to remove cellular debris. A 200 μL aliquot of supernatant was mixed with 800 μL of pre-cooled methanol (containing internal standards) to precipitate proteins, followed by vortexing and centrifugation at 12,000 g for 15 min at 4 °C. The supernatant was dried under vacuum, reconstituted in 100 μL of acetonitrile-water (9:1, v/v), and filtered through a 0.22 μm membrane before LC-MS analysis.</p>Homo sapienshttps://www.ebi.ac.uk/metabolights/MTBLS14111Wenbin Pan.Suyue Pan.Gaoling Li.Muzi Wen. Nanfang Hospital. Department of Neurology, Nanfang Hospital, Southern Medical University, Guangzhou Road North 8838#, Guangzhou, China, 510515, China. Muzikk0080@163.com.Chao Yuan.Pei Shang. Nanfang Hospital. andy.shang666@hotmail.com.Yuqiao Liao. Nanfang Hospital. cristy_lyq@163.com.Ruoyi Zheng. Nanfang Hospital. Department of Neurology, Nanfang Hospital, Southern Medical University, Guangzhou Road North 8838#, Guangzhou, China, 510515, China;. ZhengCindy324@163.com.<p>Raw LC-MS data were imported into commercial metabolomics software (e.g., Compound Discoverer 3.3, MS-DIAL, or XCMS Online) for peak detection, alignment, noise filtering, and normalization. Internal standards were used for quality control and signal correction, and only features with consistent detection across QC samples were retained for further analysis.</p>TreatmentMuzikk0080@163.com<p>Organism: Homo sapiens (Human)</p><p>Sample type: Cerebrospinal fluid (CSF)</p><p>Treatment groups: Antiviral drugs treatment; No treatment (control)</p><p>Collection method: CSF samples were collected via lumbar puncture at the L4–L5 intervertebral space using a 22G spinal needle. Approximately 10 mL of CSF was collected from each subject and immediately stored at −80 °C until analysis.</p><p>&nbsp;</p>MetabolomicsMetabolomicsAcute disseminated encephalomyelitisEpstein-Barr Virusencephalitiscerebrospinal fluidMetabolomicsAcute disseminated encephalomyelitisEpstein-Barr Virusencephalitiscerebrospinal fluid<p>Mass spectrometric detection was carried out using a Q Exactive HF-X Orbitrap mass spectrometer (Thermo Fisher Scientific) coupled to the UHPLC system, equipped with a Heated Electrospray Ionization (HESI-II) source operating in both positive and negative ion modes. The quadrupole-Orbitrap hybrid mass analyzer was set to scan over an m/z range of 70–1050 for full MS acquisition and 50–1050 for data-dependent MS/MS acquisition, enabling high-resolution accurate mass measurement and comprehensive metabolite fragmentation analysis.</p>(+/-)-EquolProstaglandin G2Lipoxin B46Ï«-Prostaglandin I1Phenylacetylglutamine(2R)-2,3-Dihydroxypropanoic acidFolic acid13(S)-HOTrEN-Acetyl-L-histidine4-(anilinomethylidene)-3-methyl-4,5-dihydroisoxazol-5-oneDeoxyinosineCytidine-5'-monophosphateDl-3,4-Dihydroxymandelic AcidD-(-)-MannitolN-AcetylvalineIsobutyryl carnitineHexanoylglycine(+/-)5(6)-DiHET3,8,9-trihydroxy-10-propyl-3,4,5,8,9,10-hexahydro-2H-oxecin-2-oneQuercetin-3ÉÇ-D-glucosideProstaglandin H2Phenylglyoxylic acidN2-MethylguanosineFAHFA 18:2/20:4Capric acid1-MethylxanthineD-Glucuronic acidSyringic acid2-Methylbutyroylcarnitine13,14-dihydro-15-keto Prostaglandin D1Ursolic acidCapryloylglycineNeopterin6-(Dimethylamino)purinePG 16:0_18:117Ï«-HydroxyprogesteroneDl-Indole-3-lactic acidProstaglandin E2Prostaglandin E1Prostaglandin E3trans-10-Heptadecenoic AcidAgnuside20-Carboxy-Leukotriene B4Mevalonic acidPyridoxamine 5-phosphateAflatoxin G1Methyltestosterone(2E)-4-Hydroxy-3,7-dimethyl-2,6-octadien-1-yl beta-D-glucopyranosidePE 18:0_22:6PE 18:0_22:5D-(+)-Maltose(+/-)12(13)-DiHOMEGlyciteinPseudouridineIsophoroneN-Acetylneuraminic acid4-Pyridoxic acidPantothenic acid10-Undecenoic acidglutathione disulfide3-[4-(tert-butyl)anilino]-2-(3-thienylcarbonyl)acrylonitrileIsovaleric acidGuanosineN-Acetyl-L-methionine3-Hydroxydecanoic acid12(S)-HETE4-Acetamidobutyric AcidD-Glucosamine 6-phosphate5'-S-Methyl-5'-thioadenosineChenodeoxycholic AciddUDPSpiculisporic AcidGuanosine triphosphate (GTP)TriacanthineL-AnserineLPE 22:6N-{[2-(2-thienyl)-1,3-thiazol-4-yl]methyl}benzamideHexadecanedioic acidOxaceprolPC 18:0_22:43-Furoic acid3-Coumaric acid3-{[(4-amino-1,3,5-triazin-2-yl)thio]methyl}benzonitrileProstaglandin D31-(4-methylphenyl)-3-(2-pyridylthio)pyrrolidine-2,5-dioneIsorhamnetinAsp-gluNaringin8Z,11Z,14Z-Eicosatrienoic acidLPE 8:0UridineAsaraldehydeD-Gluconic acidN-Acetyl-DL-tryptophan5-Aminosalicylic Acidtrans-Petroselinic acidHomogentisic AcidVitamin B2LPC 20:3LPC 20:4Androsterone glucuronideEquolDulcitolProstaglandin A2Prostaglandin A3Testosterone sulfateOrotidine 5'-monophosphateDL-3,4-Dihydroxyphenyl glycolPE 18:1_22:63-benzyl-1-butyl-4-hydroxy-1,2-dihydroquinolin-2-onebeta-Nicotinamide mononucleotideGlycoursodeoxycholic acidLysope 18:12-[(4-chlorophenyl)sulfonyl]-N,N-dimethylacetamide2-HydroxyestradiolUric acidProstaglandin B2ÉÇ-EstradiolL-(+)-Tartaric acid3-Hydroxy-3-methylglutaric acid23-Norcholic acidL-TyrosineAdipamide1,5-Anhydro-D-glucitolCyclohexaneacetic acid3-Hydroxybutyric acid2-IsopropylmalatePhenylpyruvic acid2-DeoxyuridineGTPMelatoninAscorbic acidSucrose2-Methylbutyl beta-D-glucopyranoside2-Hydroxy-2-methyl-3-buten-1-yl beta-D-glucopyranosideTetradecanedioic acidPropionyl-L-carnitineDocosahexaenoic acidgamma-GlutamyltyrosineSedoheptulose 1,7-bisphosphateLPE 20:4LPE O-18:1PC(16:0/16:0)PE O-17:1_22:6PhloretinLPC 18:2Thromoboxane B1N-Acetyl-L-tyrosineTaurocholic acidgamma-Glutamylleucinegamma-GlutamylmethionineLPC 18:0LPC 18:1PC O-16:0_22:611ÉÇ-Prostaglandin E24-benzyl-N-(3,5-dichlorophenyl)-1,4-diazepane-1-carboxamidePE O-18:0_22:4Glutamic acidSuberic acid15(R),19(R)-Hydroxy prostaglandin F2Ï«5-MethylcytidineL-Threonic acidRifampicinN-Acetyl-aspartic acidD-PantethineN-Sulfo-glucosamine sodium saltD-ThreoseCitric acidL-serineProstaglandin F3Ï«(3beta,9xi)-3-(beta-D-Glucopyranosyloxy)-14-hydroxycard-20(22)-enolide2-Arachidonyl glycerol etherP-Toluenesulfonic acidProstaglandin K211-Epiprostaglandin E115(R),19(R)-Hydroxy prostaglandin F1Ï«Glycocholic acidAdenosine 3'5'-cyclic monophosphateP-Coumaroyl AgmatineLevodopa5-AminopentanoateJasmonic acidL-AscorbateTretinoin2-Hydroxycaproic acid3-Phenyllactic acidMilbemectin A411-KetoetiocholanoloneAdrenosteroneD-(+)-GalactoseAcetaminophen glucuronideIndole-3-lactic acid2-(4-aminophenoxy)isophthalonitrileOfloxacin impurity EMonobutyl phthalateTaurochenodeoxycholic acidPE O-18:0_20:42-Aminoadipic acidVanillyl alcoholAdenosine 5'-phosphosulfate23-Nordeoxycholic acidGenisteinPG 18:0_18:1HydrocortisoneN-Acetyl-Dl-glutamic acid10-Hydroxydecanoic acidEthyl-ÉÇ-D-glucuronidecis-Aconitic acid4-Hydroxy-3- methoxyphenylglycol sulfate7-Ketolithocholic acidD(-)-AmygdalinGlycochenodeoxycholic acid1-Methyluric acid(©I)9-HpODEN-AcetylalaninePunicic AcidCTPTaurineL-Cysteine-glutathione gisulfideGamma-Glu-LeuDL-4-Hydroxyphenyllactic acidÑ´-Ribono-1,4-lactoneLithocholic acidMAG (18:2)FAHFA 16:0/18:22-Hydroxyhippuric acidN-AcetylsphingosinePE O-16:1_22:6Tetrahydroaldosteroneo-Toluic Acid5-Hydroxytryptophan2-[(3S)-1-(Cyclohexylmethyl)-3-pyrrolidinyl]-5-fluoro-1H-benzimidazole4-Hydroxybenzylcyanidealpha-Ketoglutaric acidÏ«-AspartylphenylalanineLPC 14:0ST 24:2;O4Methyl 3-indolyacetateN-Acetyl-Asp-GluN-lactoyl-phenylalaninePorphobilinogenAll-cis-4,7,10,13,16-docosapentaenoic acidMAG (18:3)4-OxoprolineL-ArabinitolIbuprofen metabolite BN6-Succinyl AdenosineChlortetracyclinePE-Cer 12:1;2O/22:0Lauric acidCalcitriol6-bromo-3-(2-phenylethanhydrazonoyl)-2H-chromen-2-one6-Deoxy-D-glucose3,5-dimethyl-N'-[4-(trifluoromethyl)benzoyl]isoxazole-4-carbohydrazideL-Tryptophan4-ButylresorcinolPentadecanoic acidN'-(4-methoxybenzoyl)-2-[(1-naphthylmethyl)thio]acetohydrazideLPC 15:013,14-Dihydro-15-keto Prostaglandin A2SerotoninFAHFA 18:0/20:2Ferulic acid8,15-Dihete2-Methoxyestradiol2-(Formylamino)Benzoic AcidLevothyroxineLysoPE 18:019(R)-Hydroxy prostaglandin F2Ï«Eicosapentaenoic acidLysopc 17:0Mycophenolic acidD-Xylonic Acid4-Hydroxybutyric acid (GHB)Dehydrocholic acidD-(-)-Glutamine5-Aminolevulinic acidCaprylic acid17(S)-HpDHACortodoxone(S)-Leucic acid6-phospho-D-glucono-1,5-lactoneLPC 16:0LPC 16:1N2,N2-DimethylguanosineLauric acid ethyl esterDehydroepiandrosteroneN-acetyl-L-ornithine1-(4-Methoxyphenyl)-2-propanoneL-MalateGluconolactoneIsorhapontigenin2-Phenylpropionic acid4-[2-(2-oxo-1-imidazolidinyl)ethyl]-1lambda~6~,4-thiazinane-1,1-dioneLNAPE 16:0/N-20:0N-Acetyl-DL-phenylalanineHippuric acid15-OxoEDEmethadone-d9N1-[3-(acetylamino)-2-oxo-2H-chromen-6-yl]-4-nitrobenzamideHomovanillic acidL-(-)-Glyceric acidTriiodothyronine2-Hydroxybutyric acidQuinolinic acid5-MethyluridineD-Ala-D-AlaJWH 018 N-pentanoic acid metaboliteGly-PheD-ProlineCitraconic acidPurineCorchorifatty acid F16-(Hexopyranosyloxy)-7-hydroxy-8,9-epoxypimaran-18-oic acidOxoadipic AcidGlycerophospho-N-palmitoyl ethanolamineDl-3-Hydroxy-kynurenineCholic acidNeohesperidinPalmitic acidArachidonic acidisoleucine2,3-dinor Prostaglandin E1PA 18:0_18:2D-(+)-Mannose16-Hydroxyhexadecanoic acidalpha-D-Glucopyranosyl 2-O-(2-methylbutanoyl)-alpha-D-glucopyranosideEthylmalonic acid3-[(methoxycarbonyl)amino]-2,2,3-trimethylbutanoic acid13-Hpotre(R)PG 18:1_18:14-Hydroxybenzoic acid3-[3-(beta-D-Glucopyranosyloxy)-2-hydroxyphenyl]propanoic acidSoyasaponin IMaltotrioseN-Acetyl-1-aspartylglutamic acidValproic acidSebacic acidN-PhenylacetylglutamineQuercetinPC 16:0_20:5N4-AcetylcytidinePC O-18:0_22:6Nicotinamide3-Methyl-2-oxobutanoic acidTheophylline3-(3-Methoxyphenyl)propionic acid(©I)5(6)-DiHETCyclohexylsulfamateEthylmalonate3-Indoxyl sulphate4-Methyl-2-Oxopentanoic Acid3-Methylglutaric acidLPC 22:62-Hydroxyvaleric acidQuinoline-4-carboxylic acidD-GlucarateThr-LeuN-Acetyl-DL-serine2-{2-oxo-2-[(2-oxo-3-azepanyl)amino]ethoxy}acetic acidKynurenineLuteolinRibulose-5-phosphate(+/-)9,10-dihydroxy-12Z-octadecenoic acid4-MethylphenolAscorbyl palmitateDodecanedioic acidÏ«-CyclodextrinXanthineSM 8:1;2O/34:0beta-Estradiol 17-AcetateLPE 18:119(R)-hydroxy Prostaglandin A2Ï«-D-Glucose-1,6-bisphosphateLPE 18:3L-Threonic acid Calcium SaltDeoxyguanosine diphosphate (dGDP)FAHFA 14:0/16:2Aldosterone3-Hydroxysebacic acidD-Fructose 6-phosphateL-Glutathione (reduced)Nicotinamide N-oxideLPC O-16:0LPC O-16:113,14-dihydro-15-keto-tetranor Prostaglandin D2LNAPE 22:4/N-18:02-[(4,6-dichloro-1,3-benzothiazol-2-yl)thio]anilineGluconic acidInositol7-MethylxanthineN-Acetylglycine1,7-Bis(4-hydroxyphenyl)-3,5-heptanediol2-Hydroxy-3-methylbutanoic acidethyl 4-chloro-3-[(3,5-dichloro-2-hydroxybenzylidene)amino]benzoateN-Acetyl-D-alloisoleucineErythronolactonePhenobarbitaldiethyl 2-{[2-(2,4-dichlorophenoxy)anilino]methylidene}malonateDl-Lanthionine2-Hydroxybenzaldehyde N-(4,6-dichloro-1,3-benzothiazol-2-yl)hydrazoneThiodiglycolic acid1a,1b-Dihomo prostaglandin E1Lipoic acidalbiflorin3-Oxo-7alpha,12alpha-hydroxy-5beta-cholanoic acidPC O-18:1_16:0Azelaic acid2-(Dimethylamino)GuanosineSM 8:1;2O/24:0O1-[4-(tert-butyl)benzoyl]-2-(tert-butylsulfonyl)ethanehydroximamideDimetghyl 4-Hydroxyisophthalate5-Methoxyindole-3-Carbaldehyde2-Hydroxy-4-methylthiobutanoic acidPC O-16:1_22:6RutinDeoxycholic acidGlycodeoxycholic acidEstroneD-2-Aminoadipic acidBiopterinN1-[4-(2-thienylthio)phenyl]-4-chlorobenzamideMestranolLPE 16:02-Methoxyestradiol (2-MeOE2)N1-(2-methyl-4-nitrophenyl)acetamidefalseCharacterization Epstein-Barr Virus-Associated Encephalitis via Identification of Metabolomic Biomarkers<p>Objective:&nbsp;Fulminant Epstein-Barr Virus (EBV) infection may lead to fatal outcomes in patients with EBV-associated encephalitis (EBVAE). To investigate potential&nbsp;biomarkers in EBVAE, we utilized an untargeted metabolomic methodology to identify disease-associated biomarkers in patients with EBVAE.&nbsp;</p><p>Methods:&nbsp;Cerebrospinal fluid (CSF) from 15 patients with EBVAE and 6 control subjects with functional neurological disorders were collected and analyzed utilizing untargeted metabolomics. Metabolites were annotated, clustered, and subjected to statistical analysis.</p><p>Results:&nbsp;Significant metabolomic alterations were observed between EBVAE patients and controls:&nbsp;164&nbsp;CSF metabolites were identified to be upregulated and&nbsp;115&nbsp;downregulated in patients with EBVAE. Among those, serotonin and tryptophan were markedly elevated in patients with EBVAE. Interestingly, 6 patients tested positive for glial fibrillary acidic protein (GFAP) antibodies in CSF met the criteria for GFAP-astrocytopathy (GFAP-A). Astrocytic&nbsp;monoamine derivative methylphenyl ethylene glycol was significantly elevated in GFAP-A subgroup compared with GFAP Ab-negative group. 6 out of 15 patients with EBVAE progressed to acute disseminated encephalomyelitis (ADEM). Gamma-aminobutyric acid (GABA) was found to be negatively correlated with Glasgow Coma Scale (GCS) scores (r = -0.858, p &lt; 0.001) in the ADEM subgroup.</p><p>Conclusion:&nbsp;Our study first characterizes the metabolomic profile of patients with EBVAE, including those with EBV positive GFAP-A or ADEM.&nbsp;</p>2026-03-232026-03-23MTBLS14111Com_27_posCom_28_posCom_35_posCom_39_posCom_50_posCom_54_posCom_64_posCom_70_posCom_76_posCom_82_posCom_89_posCom_107_posCom_137_posCom_183_posCom_211_posCom_221_posCom_304_posCom_321_posCom_373_posCom_375_posCom_391_posCom_404_posCom_516_posCom_548_posCom_562_posCom_565_posCom_573_posCom_606_posCom_612_posCom_729_posCom_738_posCom_781_posCom_793_posCom_806_posCom_940_posCom_1048_posCom_1156_posCom_1236_posCom_1259_posCom_1293_posCom_1486_posCom_1870_posCom_1988_posCom_2166_posCom_2463_posCom_2773_posCom_2990_posCom_2996_posCom_3837_posCom_4132_posCom_4248_posCom_4441_posCom_4462_posCom_4825_posCom_7938_posCom_7975_posCom_8364_posCom_8526_posCom_12474_posCom_12996_posCom_9_posCom_33_posCom_41_posCom_43_posCom_47_posCom_72_posCom_98_posCom_114_posCom_206_posCom_452_posCom_839_posCom_1105_posCom_1419_posCom_2096_posCom_2161_posCom_2193_posCom_2734_posCom_3311_posCom_3630_posCom_3750_posCom_5800_posCom_7700_posCom_22_posCom_23_posCom_36_posCom_49_posCom_56_posCom_68_posCom_80_posCom_96_posCom_102_posCom_127_posCom_131_posCom_153_posCom_158_posCom_162_posCom_175_posCom_246_posCom_249_posCom_252_posCom_263_posCom_271_posCom_282_posCom_311_posCom_327_posCom_337_posCom_338_posCom_345_posCom_363_posCom_367_posCom_400_posCom_428_posCom_429_posCom_446_posCom_458_posCom_482_posCom_510_posCom_511_posCom_519_posCom_538_posCom_593_posCom_609_posCom_647_posCom_656_posCom_670_posCom_703_posCom_718_posCom_730_posCom_743_posCom_747_posCom_750_posCom_756_posCom_779_posCom_780_posCom_794_posCom_808_posCom_825_posCom_827_posCom_881_posCom_903_posCom_905_posCom_920_posCom_927_posCom_941_posCom_944_posCom_945_posCom_1021_posCom_1037_posCom_1054_posCom_1075_posCom_1175_posCom_1207_posCom_1209_posCom_1215_posCom_1226_posCom_1243_posCom_1250_posCom_1255_posCom_1257_posCom_1288_posCom_1289_posCom_1296_posCom_1388_posCom_1405_posCom_1408_posCom_1412_posCom_1443_posCom_1481_posCom_1485_posCom_1498_posCom_1602_posCom_1629_posCom_1690_posCom_1709_posCom_1713_posCom_1783_posCom_1785_posCom_1797_posCom_1798_posCom_1825_posCom_1846_posCom_1880_posCom_1899_posCom_1918_posCom_1934_posCom_1939_posCom_1941_posCom_1948_posCom_1952_posCom_1958_posCom_1990_posCom_1991_posCom_2048_posCom_2076_posCom_2088_posCom_2114_posCom_2117_posCom_2172_posCom_2180_posCom_2203_posCom_2286_posCom_2296_posCom_2318_posCom_2340_posCom_2391_posCom_2408_posCom_2417_posCom_2443_posCom_2542_posCom_2547_posCom_2554_posCom_2568_posCom_2572_posCom_2582_posCom_2642_posCom_2669_posCom_2682_posCom_2685_posCom_2691_posCom_2735_posCom_2737_posCom_2760_posCom_2781_posCom_2791_posCom_2802_posCom_2809_posCom_2825_posCom_2872_posCom_2878_posCom_2916_posCom_2921_posCom_2958_posCom_2988_posCom_3038_posCom_3039_posCom_3094_posCom_3110_posCom_3221_posCom_3224_posCom_3241_posCom_3278_posCom_3284_posCom_3367_posCom_3378_posCom_3405_posCom_3420_posCom_3435_posCom_3436_posCom_3496_posCom_3504_posCom_3506_posCom_3527_posCom_3533_posCom_3541_posCom_3564_posCom_3584_posCom_3599_posCom_3605_posCom_3643_posCom_3647_posCom_3672_posCom_3692_posCom_3744_posCom_3767_posCom_3776_posCom_3777_posCom_3828_posCom_3840_posCom_3895_posCom_3948_posCom_3955_posCom_3962_posCom_4006_posCom_4041_posCom_4054_posCom_4057_posCom_4087_posCom_4122_posCom_4135_posCom_4174_posCom_4324_posCom_4347_posCom_4355_posCom_4378_posCom_4403_posCom_4406_posCom_4448_posCom_4506_posCom_4512_posCom_4537_posCom_4553_posCom_4598_posCom_4708_posCom_4719_posCom_4736_posCom_4747_posCom_4795_posCom_4921_posCom_4933_posCom_4963_posCom_5046_posCom_5052_posCom_5068_posCom_5084_posCom_5198_posCom_5203_posCom_5244_posCom_5251_posCom_5260_posCom_5392_posCom_5410_posCom_5426_posCom_5456_posCom_5458_posCom_5476_posCom_5507_posCom_5525_posCom_5539_posCom_5572_posCom_5638_posCom_5643_posCom_5661_posCom_5687_posCom_5723_posCom_5761_posCom_5803_posCom_5831_posCom_5912_posCom_5939_posCom_5966_posCom_5972_posCom_5991_posCom_6020_posCom_6039_posCom_6082_posCom_6109_posCom_6114_posCom_6144_posCom_6171_posCom_6194_posCom_6207_posCom_6227_posCom_6253_posCom_6276_posCom_6307_posCom_6324_posCom_6331_posCom_6357_posCom_6382_posCom_6388_posCom_6482_posCom_6535_posCom_6648_posCom_6678_posCom_6694_posCom_6705_posCom_6741_posCom_6748_posCom_6766_posCom_6772_posCom_6856_posCom_6881_posCom_6936_posCom_6954_posCom_7027_posCom_7050_posCom_7154_posCom_7159_posCom_7167_posCom_7172_posCom_7180_posCom_7205_posCom_7236_posCom_7276_posCom_7290_posCom_7327_posCom_7329_posCom_7339_posCom_7364_posCom_7371_posCom_7464_posCom_7498_posCom_7502_posCom_7524_posCom_7534_posCom_7541_posCom_7551_posCom_7613_posCom_7617_posCom_7721_posCom_7754_posCom_7766_posCom_7806_posCom_7814_posCom_7858_posCom_7860_posCom_7863_posCom_7875_posCom_7895_posCom_7950_posCom_8142_posCom_8177_posCom_8179_posCom_8189_posCom_8201_posCom_8220_posCom_8240_posCom_8266_posCom_8332_posCom_8335_posCom_8365_posCom_8454_posCom_8460_posCom_8504_posCom_8524_posCom_8587_posCom_8645_posCom_8664_posCom_8673_posCom_8681_posCom_8688_posCom_8691_posCom_8695_posCom_8701_posCom_8815_posCom_8861_posCom_8879_posCom_8975_posCom_8990_posCom_9039_posCom_9102_posCom_9241_posCom_9273_posCom_9297_posCom_9408_posCom_9435_posCom_9439_posCom_9501_posCom_9534_posCom_9576_posCom_9582_posCom_9594_posCom_9642_posCom_9668_posCom_9669_posCom_9734_posCom_9747_posCom_9751_posCom_9781_posCom_9793_posCom_9798_posCom_9801_posCom_9836_posCom_9840_posCom_9858_posCom_9929_posCom_9931_posCom_9988_posCom_9991_posCom_10049_posCom_10140_posCom_10160_posCom_10276_posCom_10281_posCom_10337_posCom_10396_posCom_10398_posCom_10426_posCom_10568_posCom_10601_posCom_10620_posCom_10731_posCom_10741_posCom_10786_posCom_10837_posCom_10840_posCom_10874_posCom_10887_posCom_11088_posCom_11152_posCom_11179_posCom_11190_posCom_11212_posCom_11265_posCom_11291_posCom_11308_posCom_11312_posCom_11357_posCom_11359_posCom_11427_posCom_11460_posCom_11481_posCom_11495_posCom_11534_posCom_11558_posCom_11614_posCom_11638_posCom_11653_posCom_11666_posCom_11678_posCom_11684_posCom_11745_posCom_11807_posCom_11940_posCom_11966_posCom_12026_posCom_12034_posCom_12061_posCom_12085_posCom_12169_posCom_12179_posCom_12258_posCom_12264_posCom_12278_posCom_12322_posCom_12349_posCom_12369_posCom_12370_posCom_12392_posCom_12442_posCom_12526_posCom_12557_posCom_12584_posCom_12755_posCom_12898_posCom_13013_posCom_13036_posCom_13040_posCom_13052_posCom_13117_posCom_13143_posCom_13411_posCom_13422_posCom_13508_posCom_13572_posCom_13584_posCom_13590_posCom_13634_posCom_13644_posCom_13646_posCom_13674_posCom_13684_posCom_13757_posCom_13797_posCom_13826_posCom_13850_posCom_13854_posCom_13909_posCom_13962_posCom_14011_posCom_14135_posCom_14160_posCom_14198_posCom_14222_posCom_14224_posCom_14253_posCom_14287_posCom_14318_posCom_14436_posCom_14462_posCom_14587_posCom_14737_posCom_15056_posCom_15070_posCom_15097_posCom_15164_posCom_15168_posCom_15271_posCom_15412_posCom_15429_posCom_15649_posCom_15669_posCom_15689_posCom_15925_posCom_15980_posCom_16010_posCom_16028_posCom_16068_posCom_16161_posCom_16164_posCom_16218_posCom_16599_posCom_16603_posCom_16649_posCom_16824_posCom_16865_posCom_16933_posCom_16994_posCom_17060_posCom_17079_posCom_17207_posCom_17502_posCom_17545_posCom_17586_posCom_17719_posCom_17836_posCom_51_posCom_97_posCom_157_posCom_172_posCom_226_posCom_325_posCom_403_posCom_430_posCom_467_posCom_495_posCom_566_posCom_669_posCom_752_posCom_760_posCom_958_posCom_1061_posCom_1131_posCom_1281_posCom_1457_posCom_1543_posCom_1559_posCom_1734_posCom_1776_posCom_2006_posCom_2047_posCom_2153_posCom_2182_posCom_2225_posCom_2242_posCom_2526_posCom_2577_posCom_3006_posCom_3036_posCom_3096_posCom_3237_posCom_3338_posCom_3762_posCom_4094_posCom_4139_posCom_4561_posCom_4663_posCom_5004_posCom_5057_posCom_5367_posCom_5485_posCom_5652_posCom_5701_posCom_6017_posCom_6225_posCom_6606_posCom_6771_posCom_7516_posCom_7853_posCom_8016_posCom_8634_posCom_8669_posCom_9268_posCom_10341_posCom_10486_posCom_11016_posCom_11682_posCom_12547_posCom_12905_posCom_13433_posCom_13585_posCom_13625_posCom_14454_posCom_14862_posCom_15375_posCom_15427_posCom_15865_posCom_2_negCom_4_negCom_20_negCom_24_negCom_40_negCom_68_negCom_77_negCom_84_negCom_99_negCom_115_negCom_137_negCom_197_negCom_231_negCom_232_negCom_250_negCom_253_negCom_366_negCom_423_negCom_451_negCom_513_negCom_516_negCom_645_negCom_683_negCom_1039_negCom_1060_negCom_1575_negCom_1641_negCom_1668_negCom_2192_negCom_2433_negCom_3967_negCom_4750_negCom_6530_negCom_6579_negCom_10560_negCom_11998_negCom_13743_negCom_16923_negCom_18_negCom_11_negCom_160_negCom_60_negCom_95_negCom_242_negCom_80_negCom_361_negCom_538_negCom_828_negCom_2482_negCom_970_negCom_1159_negCom_1279_negCom_2979_negCom_846_negCom_4403_negCom_890_negCom_9532_negCom_6085_negCom_1658_negCom_106_negCom_212_negCom_5_negCom_7_negCom_8_negCom_17_negCom_41_negCom_53_negCom_61_negCom_62_negCom_66_negCom_67_negCom_150_negCom_168_negCom_185_negCom_269_negCom_276_negCom_290_negCom_304_negCom_338_negCom_341_negCom_356_negCom_367_negCom_370_negCom_399_negCom_400_negCom_402_negCom_408_negCom_413_negCom_452_negCom_466_negCom_490_negCom_492_negCom_564_negCom_571_negCom_582_negCom_604_negCom_640_negCom_668_negCom_739_negCom_741_negCom_773_negCom_774_negCom_805_negCom_851_negCom_856_negCom_866_negCom_902_negCom_944_negCom_948_negCom_1021_negCom_1062_negCom_1068_negCom_1078_negCom_1214_negCom_1288_negCom_1294_negCom_1306_negCom_1316_negCom_1319_negCom_1336_negCom_1453_negCom_1460_negCom_1462_negCom_1532_negCom_1815_negCom_1820_negCom_1870_negCom_1893_negCom_1920_negCom_2019_negCom_2036_negCom_2068_negCom_2085_negCom_2114_negCom_2135_negCom_2242_negCom_2245_negCom_2369_negCom_2392_negCom_2394_negCom_2499_negCom_2570_negCom_2644_negCom_2739_negCom_2793_negCom_2801_negCom_2812_negCom_2814_negCom_2825_negCom_2866_negCom_2874_negCom_2915_negCom_2933_negCom_2954_negCom_3061_negCom_3161_negCom_3268_negCom_3322_negCom_3445_negCom_3588_negCom_3618_negCom_3628_negCom_3659_negCom_3719_negCom_3724_negCom_3780_negCom_3816_negCom_3844_negCom_3868_negCom_3946_negCom_4058_negCom_4247_negCom_4298_negCom_4560_negCom_4621_negCom_4637_negCom_4664_negCom_4729_negCom_4803_negCom_4833_negCom_4955_negCom_5133_negCom_5141_negCom_5182_negCom_5257_negCom_5290_negCom_5329_negCom_5521_negCom_5607_negCom_5806_negCom_5874_negCom_5918_negCom_5951_negCom_6069_negCom_6153_negCom_6334_negCom_6416_negCom_6480_negCom_6517_negCom_6694_negCom_6734_negCom_6800_negCom_7012_negCom_7217_negCom_7448_negCom_7456_negCom_7461_negCom_7502_negCom_7556_negCom_7631_negCom_7632_negCom_7656_negCom_7889_negCom_8054_negCom_8083_negCom_8095_negCom_8119_negCom_8296_negCom_8321_negCom_8335_negCom_8435_negCom_8483_negCom_8577_negCom_8658_negCom_8704_negCom_8763_negCom_8843_negCom_8901_negCom_9077_negCom_9198_negCom_9244_negCom_9287_negCom_9405_negCom_9461_negCom_9664_negCom_9832_negCom_9846_negCom_9939_negCom_9960_negCom_10096_negCom_10156_negCom_10387_negCom_10620_negCom_10676_negCom_10687_negCom_10720_negCom_10733_negCom_10968_negCom_11002_negCom_11109_negCom_11252_negCom_11259_negCom_11384_negCom_11440_negCom_11484_negCom_11501_negCom_11513_negCom_11622_negCom_11655_negCom_11688_negCom_11774_negCom_11869_negCom_11917_negCom_12198_negCom_12224_negCom_12259_negCom_12279_negCom_12497_negCom_12685_negCom_12764_negCom_12835_negCom_12837_negCom_12845_negCom_12877_negCom_12885_negCom_12987_negCom_13112_negCom_13169_negCom_13208_negCom_13330_negCom_13443_negCom_13496_negCom_13555_negCom_13708_negCom_13929_negCom_13935_negCom_14102_negCom_14281_negCom_14293_negCom_14510_negCom_14550_negCom_14560_negCom_14705_negCom_14719_negCom_14895_negCom_14918_negCom_14949_negCom_15355_negCom_15461_negCom_15725_negCom_15729_negCom_15799_negCom_15801_negCom_15898_negCom_15938_negCom_15943_negCom_15957_negCom_16193_negCom_16216_negCom_16248_negCom_16375_negCom_16378_negCom_16414_negCom_16749_negCom_16782_negCom_16986_negCom_17621_negCom_17633_negCom_17730_negCom_17857_negCom_17986_negCom_18220_negCom_18339_negCom_18547_negCom_18632_negCom_18715_negCom_18751_negCom_18761_negCom_18807_negCom_18966_negCom_18972_negCom_19168_negCom_19177_negCom_19198_negCom_19230_negCom_19331_negCom_19819_negCom_19970_negCom_20366_negCom_20643_negCom_25_negCom_109_negCom_70_negCom_159_negCom_1389_negCom_113_negCom_174_negCom_588_negCom_386_negCom_1317_negCom_270_negCom_329_negCom_1216_negCom_6507_negCom_6162_negCom_983_negCom_272_negCom_2093_negCom_1302_negCom_6725_negCom_12901_negCom_686_negCom_3804_negCom_768_negCom_1945_negCom_123_negCom_4200_negCom_16113_negCom_14533_negCom_2389_negCom_265_negCom_1964_negCom_2380_negCom_13974_negCom_4691_negCom_342_negCom_19215_negCom_1687_negCom_2050_negCom_1293_negCom_9569_negCom_16290_negCom_8953_negCom_13785_negCom_4695_negCom_299_negCom_4933_negCom_8709_negCom_6491_negCom_1776_negCom_1785_negCom_5232_negCom_960_negCom_35_negCom_3152_negCom_1390_negCom_682_negCom_2505_negCom_2705_negCom_4299_negCom_7793_negCom_4025_negCom_3388_negCom_3350_negCom_2957_negCom_2438_negCom_154_negCom_10037_negCom_1493_negCom_3202_negCom_17513_negCom_1027_negCom_2175_negCom_19691_negCom_5333_negCom_7734_negCom_4778_negCom_1607_negCom_8074_negCom_3484_negCom_4653_negCom_6550_negCom_9770_negCom_6235_negCom_9353_negCom_8850_neg